TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCON Stock Price Chart Interactive Chart >
TCON Price/Volume Stats
| Current price | $1.35 | 52-week high | $3.79 |
| Prev. close | $1.41 | 52-week low | $1.24 |
| Day low | $1.31 | Volume | 89,500 |
| Day high | $1.42 | Avg. volume | 87,104 |
| 50-day MA | $1.57 | Dividend yield | N/A |
| 200-day MA | $1.92 | Market Cap | 28.92M |
TRACON Pharmaceuticals, Inc. (TCON) Company Bio
Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.
Latest TCON News From Around the Web
Below are the latest news stories about TRACON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TCON as an investment opportunity.
Revisiting TRACON Pharmaceuticals (NASDAQ:TCON)TRACON''s primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors. Read more to see TCON''s investment analysis. |
TRACON Pharmaceuticals (TCON) Receives a Buy from Maxim GroupMaxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON - Research Report) yesterday and set a price target of $8.00. The company's shares opened today at $1.44.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -37.8% and a 14.69% success rate on recommended stocks. Currently, the analyst consensus on TRACON Pharmaceuticals is a Strong Buy with an average price target of $8.33, representing a 478.47% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target. |
H.C. Wainwright Sticks to Its Buy Rating for TRACON Pharmaceuticals (TCON)H.C. Wainwright analyst Edward White reiterated a Buy rating on TRACON Pharmaceuticals (TCON - Research Report) today and set a price target of $12.00. The company's shares opened today at $1.44.White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Valneva, and Spectrum Pharmaceuticals. According to TipRanks, White has an average return of -21.8% and a 26.45% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for TRACON Pharmaceuticals with a $8.33 average price target, which is a 478.47% upside from current levels. |
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line SarcomaSAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced dosing of the first patient in a Phase 1/2 trial evaluating the Company’s CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubi |
Maxim Group Remains a Buy on TRACON Pharmaceuticals (TCON)Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON - Research Report) yesterday and set a price target of $8.00. The company's shares opened today at $1.51.According to TipRanks, McCarthy is an analyst with an average return of -38.2% and a 16.67% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals.Currently, the analyst consensus on TRACON Pharmaceuticals is a Strong Buy with an average price target of $8.33, representing a 451.66% upside. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $5.00 price target. |
TCON Price Returns
| 1-mo | -11.18% |
| 3-mo | -33.17% |
| 6-mo | -8.16% |
| 1-year | -50.55% |
| 3-year | -53.77% |
| 5-year | -95.50% |
| YTD | -51.26% |
| 2021 | -76.32% |
| 2020 | 400.00% |
| 2019 | -62.86% |
| 2018 | -81.19% |
| 2017 | -31.63% |
Loading social stream, please wait...